TrialRMD open2022

Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.

Fengchun Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.